Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: A randomised controlled trial

The Lancet Oncology

Volumn 12, Issue 9, 2011, Pages 871-879

  Di Stasi, Savino M ^a,b   Valenti, Marco ^c   Verri, Cristian ^a   Liberati, Emanuele ^b   Giurioli, Arcangelo ^d   Leprini, Gioia ^a   Masedu, Francesco ^c   Ricci, Antonio R ^e   Micali, Francesco ^b   Vespasiani, Giuseppe ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d A Perrino Hospital   (Italy)

^e SANDRO PERTINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN;

ARTHRALGIA; ARTICLE; BLADDER CANCER; BLADDER PERFORATION; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CHEMICAL CYSTITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYSTITIS; DIFFUSION; DISEASE FREE INTERVAL; DRUG HYPERSENSITIVITY; DRUG INSTILLATION; DRUG WITHDRAWAL; ELECTROMOTIVE DRUG ADMINISTRATION; GRANULOMATOUS PROSTATITIS; HEMATURIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; PASSIVE DIFFUSION; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PRIMARY UROTHELIAL NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF BLADDER TUMOR; TREATMENT DURATION; URETER OBSTRUCTION; URINARY FREQUENCY;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; ELECTROCHEMOTHERAPY; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 80052376049     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70190-5     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. Ca Cancer J Clin 2011, 61:69-90.
2. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475.
4. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomic 2003, 21:1315-1330.
5. Weldon TE, Soloway MS Susceptibility of urothelium to neoplastic cellular implantation. Urology 1975, 5:824-827.
6. Sylvester RJ, Oosterlinck W, van der Mejiden APM A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004, 171:2186-2190.
7. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
8. Berrum-Svennung I, Gransfors T, Jahnson S, Boman H, Holmang S A single instillation of epirubicin after transurethral resection of bladder tumours prevent only small recurrences. J Urol 2008, 179:101-106.
9. Gudjónsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009, 55:773-780.
10. Dobruch J, Herr H Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?. BJU Int 2009, 104:170-174.
11. Cai T, Nesi G, Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008, 180:110-115.
12. Böhle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 2009, 56:495-503.
13. O'Donnel MA When medical evidence alone is simply not enough. Cancer 2009, 115:2602-2604.
14. Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999, 59:4912-4918.
15. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C vs passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003, 170:777-782.
16. Mostofi FK, Sobin LH, Torloniu H Histological typing of urinary bladder tumours: International Classification of Tumours, No 10 1973, World Health Organization, Geneva.
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1928, 5:649-655.
18. Gontero P, Cattel L, Paone TC, et al. Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int 2010, 106:1652-1656.
19. Di Stasi SM, Riedl C Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 2009, 27:325-330.
20. Sobin LH, Wittekind CH UICC (International Union Against Cancer): TNM classification of malignant tumours 1997, 107-190. Wiley Liss, New York, NY. 5th edn.
21. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995, 153:1444-1450.
22. Feifer A, Xuanqian X, Brophy JM, Segal R, Kassouf W Contemporary cost analysis of single instillation of mytomicin after transurethral resection of bladder tumour in a universal health care system. Urology 2010, 76:652-657.
23. Morgan TM, Keegan KA, Clark PE Bladder cancer. Curr Opin Oncol 2011, 23:275-282.
24. Di Stasi SM, Giannantoni A, Capelli G, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006, 7:43-51.
25. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R Effectiveness of single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol 1999, 161:1120-1123.
26. Levin DR, Moskovitz B Distilled water versus chemotherapeutic agents for transitional bladder carcinoma. Eur Urol 1986, 12:418-421.
27. Bolkier M, Moskovitz B, Ginesin Y, Levin DR Effect of distilled water and bacillus Calmette-Guerin on exfoliated bladder tumor cells. Eur Urol 1991, 19:319-321.
28. Fechner G, Pocha K, Schmidt D, Müller SC Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs mitomycin. Int J Clin Pract 2006, 60:1178-1180.
29. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993, 149:749-752.
30. Sangeda RZ, Vandepitte J, Huygens A, Van Cleynenbreugel B, Van Poppel H, de Witte PA Prevention of tumor cell reimplantation during transurethral resection: the in-vitro antiadhesive and cytotoxic properties of an irrigant containing polyethylene glycol 400. Anticancer Drugs 2010, 21:645-650.
31. Cina SJ, Epstein JI, Endrizzi JM, Harmon WJ, Schoenberg MP Consideration of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol 2001, 32:630-637.
32. Shapiro O, Jones K, Wang C, Landas S, Haas GP Risk of postoperative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol 2006, 13:3317-3320.
33. Tyritzis SI, Stravodimos KG, Mihalakis A, Costantinides CA Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours. Int Urol Nephrol 2009, 41:865-868.
34. Balbay MD, Çimentepe E, Ünsal A, Bayrak Ö, Koç A, Akbulut Z The actual incidence of bladder perforation following transhrethral bladder surgery. J Urol 2005, 174:2260-2263.